Top 10 Undervalued Stocks To Invest In 2018


Amaya’s stock has been on a wild roller coaster ride this year, with catalysts ranging from the CEO (David Baazov) being accused of insider trading, to takeover rumors, to failed mergers and now a formal bid by the aforementioned CEO. There have certainly been a lot of hopes and headaches, but I believe there is a strong underlining long case to be made on Amaya. I wrote a blog post about it the day before it released its Q3 earnings, my basic argument was that it is intrinsically undervalued due to market overreaction on merger discussions and there was still the possibility of a buyout by the former CEO at a significant upside. It seemed like a win-win. Well, when the earnings were released, not only were the results impressive but Baazov launched a formal bid at C$24 per share (approximately US$18) or a 30% upside from the previous Friday’s Close. Whether this private takeover succeeds or not, this stock is poised for significant long term growth.


Amaya (NASDAQ:AYA) runs the world’s largest online gaming (casino) empire in the world. It runs many valuable brand names especially in the online poker business (PokerStars and Fulltilt) but is now increasingly moving into sports betting and other online casino games. It is also the fastest growing and most well positioned to take advantage of online gambling legalization as well as the inherent scalability of the internet. This is a company which has seen its revenues increase from below US$200M just a few years ago to over US$1.2 BILLION for the trailing twelve months. Reviewing its results and its future growth prospects, it will be clear that this firm is undervalued.

Top 10 Undervalued Stocks To Invest In 2018: Regeneron Pharmaceuticals, Inc.(REGN)


Advisors’ Opinion:

  • [By Ben Levisohn]

    Regeneron Pharmaceuticals (REGN) soared to the top of the S&P 500 today after a competitor’s competing drug failed a Phase 3 trial.

    Getty Images

    Regenerongained 3.8% to $387.10 today, while the S&P 500 declined 0.1% to 2,256.96.

    RBC’s Adnan Butt and Michael Yee offer their take:

    Two Phase 3 studies comparing Ophthotechs (OPHT) Fovista plus Lucentis to Lucentis alone did not meet the primary endpoint of demonstrating a better vision for the combination at 12 months. The improvements were 10.24 letters for the combo vs. 10.01 for Lucentis when the two Phase 3s were combined. Individually, one Phase 3 showed combo improvement of 10.74 letters vs. 9.82 letters alone and the second 9.91 letters vs. 10.36 letters with Lucentis alone. A third Phase 3 study combining Fovista with Eylea or Avastin is ongoing…


    Big overhang removed; [Regeneron] shares should be up and then continue to rise with the focus moving to dupilumab. Overhang was that Fovista success and approval could disrupt the market for Eylea as more docs tried combining nearly free Avastin (off-label) with Fovista to improve outcomes with patients. We had always argued that even under that scenario Eylea would be used since it is the most potent agent. We are buyers at current level especially ahead of the upcoming dupilumab launch.

    Regeneron’s market capitalization rose to $51.5 billion today from $39.3 billion yesterday. It reported net income of $636 million on sales of $4.1 billion in 2015.

  • [By Ben Levisohn]

    After years of rising and falling in tandem, the biotech sector is all about stock picking now. Credit Suisse analyst Alethia Young and team, for instance, upgraded Regeneron Pharmaceuticals (REGN), and added Celgene (CELG) to its Focus List today. But Amgen (AMGN) wasn’t so lucky as Young cut it to Neutral from Outperform. She explains why:

  • [By Ben Levisohn]

    Regeneron Pharmaceuticals (REGN) tumbled to the bottom of the S&P 500 today after a judge said the company could be forced to stop selling an anti-cholesterol drug due to violating an Amgen (AMGN) patent.


    Agence France-Presse/Getty Images

    Regeneron Pharmaceuticalsdropped 5.8% to $358.68 today, while the S&P 500 rose 0.4% to 2,276.98.

    Chardan’sGbola Amusa takes a victory lap:

    Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in its favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.


    While the loss is bad news for Regeneron, Barron’s Johanna Bennettargues that it could herald a comeback for Amgen.

    Regeneron’s market capitalization fell to $38.5 billion today from $40.2 bil

Top 10 Undervalued Stocks To Invest In 2018: Caleres, Inc.(CAL)

Advisors’ Opinion:

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update.
    Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.
    The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62.
    Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold.
    Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split.
    Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period.
    AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016.
    Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli
  • [By Lisa Levin]

    Shares of Caleres Inc (NYSE: CAL) got a boost, shooting up 12 percent to $31.99 after the company posted upbeat Q3 earnings.

    QAD Inc. (NASDAQ: QADA) shares were also up, gaining 14 percent to $29.44 after the company posted strong Q3 results.

Top 10 Undervalued Stocks To Invest In 2018: CF Industries Holdings, Inc.(CF)

Advisors’ Opinion:

  • [By Shanthi Rexaline]

    Agri-Input Companies — Seeds/ Fertilizers/Pesticides Manufacturers


    Monsanto Company (NYSE: MON): +68.82 percent since 2011. Syngenta AG (ADR) (NYSE: SYT): +56.26 percent since 2011. Mosaic Co (NYSE: MOS): -63.1 percent since 2011. Potash Corporation of Saskatchewan (USA) (NYSE: POT): -67.8 percent since 2011. CF Industries Holdings, Inc. (NYSE: CF): +5.04 percent since 2011. Agrium Inc. (USA) (NYSE: AGU): +1.10 percent since 2011.

    Agri-Finance Companies

  • [By Ben Levisohn]

    CF Industries (CF) rose to the top of the S&P 500 today, continuing strength that began earlier this month.


    Getty Images

    CF Industries gained 6.9% to $28.96 today, while the S&P 500 fell 0.2% to 2,181.90. CF Industries has gained 21% in November.

    Despite the rally, CF Industries is still down 29% this year, and as recently as Nov.3, Citigroup’s P.J. Juvekar and team were writing that the fertilizer company was “looking more like a 2008 story” after weaker-than-expected earnings. Donald Trump’s election victory, however, has jumpstarted CF Industries and prompted FBN technical analystJC OHara to list it among the top-50 stocks following Trump’s election, noting that “we want to own the stocks that were first to leave the gate…New Momentum should continue.” On Nov. 9, Barron’s Michael Kahn agreed, writing that “CF Industries does merit a look.”


    CF Industries reported net income of $700 million on sales of $4.3 billion in 2015. Its market capitalization rose to $6.8 billion today from $6.3 billion yesterday.

     

  • [By Lisa Levin]

    In trading on Tuesday, basic materials shares fell 0.63 percent. Meanwhile, top losers in the sector included Myers Industries, Inc. (NYSE: MYE), down 7 percent, and CF Industries Holdings, Inc. (NYSE: CF) down 6 percent.

Top 10 Undervalued Stocks To Invest In 2018: Bavarian Nordic A/S (BVNKF)


Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Leuven, Belgium-based Tigenix (OTC:TGXSF) filed to go public in the U.S. in late 2015, only to become entangled with Bavarian Nordic (OTC:BVNKF) and Basilea Pharmaceutica (OTC:BPMUF) as the European drugmakers pulled back from NASDAQ. Tigenix subsequently increased its bank account following a 23.75 million placement in Belgium, and added an additional 25 million via a relationship with Takeda, before coming back to Wall Street in October 2016 with a revamped slate of underwriters.

Top 10 Undervalued Stocks To Invest In 2018: Virtusa Corporation(VRTU)


Advisors’ Opinion:

  • [By Lisa Levin]

    Technology shares gained around 0.85 percent in trading on Friday. Meanwhile, top gainers in the sector included Virtusa Corporation (NASDAQ: VRTU), and Ceragon Networks Ltd (NASDAQ: CRNT).

Top 10 Undervalued Stocks To Invest In 2018: Nabors Industries Ltd.(NBR)

Advisors’ Opinion:

  • [By Craig Jones]

    On CNBC's "Fast Money Halftime Report", Jon Najarian spoke about Nabors Industries Ltd. (NYSE: NBR). He said that somebody bought 6,500 contracts of the July 11 calls for $0.50 in the first half of the session. The trade breaks even at $11.50 or 16.28 percent above the current market price. Jon Najarian has a long position in the name and he is planning to hold it for a month.

  • [By Ben Levisohn]

    Last night, Weatherford International (WFT) reported a smaller than expected loss and announcing an alliance with Nabors Industries (NBR)–and the news was celebrated by the market.

  • [By Jon C. Ogg]

    Nabors Industries Ltd. (NYSE: NBR) rose by 22.3% to $16.11 on Wednesday. Its volume of 17.4 million shares was about 2.5 times normal trading volume. Nabors has a consensus analyst price target of $15.04 and a 52-week trading range of $4.93 to $16.50. The company has a total market cap of $4.6 billion.

  • [By Craig Jones]

    Pete Najarian was watching Nabors Industries Ltd. (NYSE: NBR). He said that the stock has been trading in a range between $8 and $18 over the last 52 weeks and although it spiked 2.82 percent on Wednesday, it's still close to the lower end of the range. Anticipating a move higher, traders were buying the June 11 calls for $0.30. Around 6,000 contracts were bought in the first half of the session. The trade breaks even at $11.30 or 10.78 percent above the current market price. Pete Najarian decided to buy the calls and he is going to hold them for 4-5 weeks.

  • [By Wayne Duggan]

    While Loop maintains a Buy rating on all of the stocks mentioned above, Guggenheim analyst Michael LaMotte isn’t quite so bullish on the sector. Earlier this week, LaMotte downgraded the following oil services stocks from Buy to Neutral:

    Baker Hughes Incorporated (NYSE: BHI)
    Fairmount Santrol Holdings Inc (NYSE: FMSA)
    Helmerich & Payne, Inc. (NYSE: HP)
    Nabors Industries Ltd. (NYSE: NBR)
    Schlumberger Limited. (NYSE: SLB)
    Halliburton
    Superior Energy Services

    Guggenheim also cut its 2017 oil price forecast from $55 to $48/bbl.

Top 10 Undervalued Stocks To Invest In 2018: Liquidity Services Inc.(LQDT)


Advisors’ Opinion:

  • [By Roberto Pedone]

    Liquidity Service (LQDT) is an online auction marketplace for surplus and salvage assets. This stock closed up 14.9% at $34.44 in Monday’s trading session.

    Monday’s Volume: 1.60 million

    Three-Month Average Volume: 402,622

    Volume % Change: 336%

    From a technical perspective, LQDT skyrocketed higher here right off its 50-day moving average of $30.94 with strong upside volume. This move briefly saw shares of LQDT trend back above its 200-day moving average at $34.60, before it closed just below that level at $34.44. Shares of LQDT are now quickly moving within range of triggering a big breakout trade. That trade will hit if LQDT manages to take out Monday’s intraday high of $35.21 and then once it clears some more near-term overhead resistance at $35.71 with high volume.


    Traders should now look for long-biased trades in LQDT as long as it’s trending above $32.67 or above $31.60 and then once it sustains a move or close above those breakout levels with volume that hits near or above 402,622 shares. If we get that breakout soon, then LQDT will set up to re-test or possibly take out its next major overhead resistance levels at $38 to $40.90.

  • [By Jon C. Ogg]

    Liquidity Services Inc. (NASDAQ: LQDT) was raised to Buy from Underperform, and the price target was raised up to $45 from $28.50, at Merrill Lynch.

Top 10 Undervalued Stocks To Invest In 2018: Intelligent Content Enterprises Inc. (ICEIF)


Advisors’ Opinion:

  • [By Bryan Murphy]

    In hindsight, June’s news from Intelligent Content Enterprises Inc. (OTCMKTS:ICEIF) should come as no surprise. In May the organization announced it was buying Catch Star Studios LLC for the purpose of creating its own sports-related television shows that would be aired by broadcast as well as online. Now it’s begun creating that television content, following in the footsteps of much bigger original-content creators such as Amazon.com, Inc. (NASDAQ:AMZN) and Netflix, Inc. (NASDAQ:NFLX).


    What might comes as a surprise to existing and potential ICEIF shareholders, however, is how big highly-focused original television programming is now that the lines between the internet and cable television have not only been crossed, but erased.

    May wasn’t just a pivotal month for Intelligent Content Enterprises because it’s when the acquisition of Catch Star Studios was put into motion. May was also the month Interactive Advertising Bureau (IAB) reported some stunning results of a new study about digital video-viewing habits and preferences. The key findings? Regular viewers of original digital video programming in the U.S. have grown from 45 million in 2013 to 63 million, and the advertisements displayed via a digital broadcast of such programming are liked and remembered by far more viewers than they are when part of a conventional cable television broadcast.


    Said another way as far as advertisers are concerned, the world wide web is the new cable television. That’s not to say cable television has become irrelevant. Savvy content makers are now doing both, while also making a point of creating their own customized content now that the fight for viewers has gotten brutal.

    Take Netflix as an example. It has a pair of smash hits with its self-produced ‘Orange is the New Black’ and ‘House of Cards.’ Amazon.com is getting into the game too, with its ‘Mozart in the Jungle’ recently being awarded two Golden Globes.


    This same paradigm shift h

  • [By Bryan Murphy]

    If there was any doubt that the future of video as a digital medium was here to stay, Twitter Inc (NYSE:TWTR) just wiped that doubt away. It’s going to open up its video-sharing platform to anyone — not just vetted creators with huge followings — and split ad revenue with them. In so doing, it now offers a similar deal (though a more generous deal) that Facebook Inc (NASDAQ:FB) and YouTube also offers video creators.

    It’s just a microcosm of the shape of things to come… or the shape of things as they already are. Last year was the first year internet users spent more time watching videos online than they did engaged in social media, averaging more one hour and sixteen minutes of video viewing per day.


    Perhaps more important, the amount of ad revenue the likes of Facebook, and now Twitter, generate via online video is small, but growing very fast. The total ad spend allocated for digital video has jumped from 2.4% in 2013 to 4.4% today, and that’s expected to double again in two years.

    Yet, for as much revenue as online video can drive and as big as it’s gotten, the ad-display technology remains alarmingly inelegant, even or veteran players like YouTube and Facebook. This clunky display of ads — and Twitter will likely keep it clunky, at least initially — increasingly makes a company called Intelligent Content Enterprises Inc (OTCMKTS:ICEIF) not just well-positioned, but a potential acquisition target.


    Intelligent Content Enterprises has developed a tool called Clix Video(tm), which the company described as a way to enable “digital and mobile viewers to instantaneously connect to web and mobile sites by clicking on custom interactive tags within the video broadcasts to make social media connections, to review extra and exclusive content and make online and mobile purchases directly via the video broadcast providing a richer, deeper consumer experience related to the video content. “

    In English, it just means Clix Vide

  • [By James E. Brumley]

    In May of this year, at the annual Collision Conference, advertising and media executives of the world’s biggest traffic-oriented (and ad-supported) websites asked themselves a crucial question: How do we save online advertising from itself?

    The question itself is a reflection of the new reality of the internet…. it’s become so big, so full, so cross-border, so competitive, and so promotional that it’s become an unwieldy mess. Twenty years ago, click-through rates were greater than 40%. Now they’re a mere 0.6%, as consumers (1) are saturated by marketing messages, and (2) have largely learned that ads don’t lead them to a product or service they care about. Digital advertising simply isn’t what it used to be.


    While the answer to the question “how can digital advertising be saved?” is a complex one, a company called Intelligent Content Enterprises Inc. (OTCMKTS:ICEIF) addresses at least one aspect of the question, by doing what the web’s capitalists have failed to figure out how to do well. What’s that? ICEIF understands that an ad has to be relevant to a user no matter where that user is, and that to see an ad at all, a user has to be able to read the web’s content in his or her native language.


    Intelligent Content Enterprises, through its Digital Widget Factory website www.digiwidgy.com, has tackled the aforementioned issue head-on, creating a rich website with a built-in translation tool which displays advertisements and offers unique to that reader’s location, and delivers that marketing message in his or her native language.

    It may sound like a lot of work at first glance. But, it’s worth it.

    Digital industry research outfit Common Sense Advisory reports that of the more than 3 billion internet users worldwide, approximately 73% — 2.2 Billion people — are browsing the web in a language other than English. That’s quite a disparity from the fact that more than 50% of the content on the web is na

Top 10 Undervalued Stocks To Invest In 2018: EPR Properties(EPR)


Advisors’ Opinion:

  • [By Laurie Kulikowski]

    EPR’s revenue growth has slightly outpaced the industry average of 6.1%. Since the same quarter one year prior, revenues slightly increased by 9.7%. This growth in revenue appears to have trickled down to the company’s bottom line, improving the earnings per share.

     

  • [By Laurie Kulikowski]

    EPR’s investment pipeline should drive about 6-7% earnings growth in 2016, and historically the company’s dividend growth has roughly equated to earnings growth. Starting with an above-average 6.5% yield, we find this compelling for income-oriented investors. 

  • [By Laurie Kulikowski]

    We rate EPR PROPERTIES as a Buy with a ratings score of B. This is driven by a number of strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company’s strengths can be seen in multiple areas, such as its revenue growth, increase in net income, good cash flow from operations, expanding profit margins and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. 

Top 10 Undervalued Stocks To Invest In 2018: Affimed N.V.(AFMD)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Affimed NV (NASDAQ: AFMD) were down around 21 percent to $1.70. Affimed priced its public offering of 10,000,000 of its common shares at $1.80 per common share.

Leave a Reply

Your email address will not be published.